NASDAQ · Biotechnology

Inozyme Pharma, Inc. (INZY) Stock

$4.00 +0.25% NASDAQ: INZY Healthcare

Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases.

Valuation

MetricValue
Price$4.00
Market Cap$258.25M
P/E Ratio-2.47
P/B Ratio4.34
P/S Ratio0.00
EPS (TTM)$-1.62
52-Week High$6.24
52-Week Low$0.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-102.90%
ROA-82.82%
ROCE-116.52%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.81
Current Ratio3.56

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-57.0M$-57.0M$-69.0M$-76.0M$-104.0M
Net Profit$-56.0M$-56.0M$-65.0M$-71.0M$-102.0M
EPS$-2.39$-2.39$-1.73$-1.37$-1.62
Op Margin—————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$169.0M$124.0M$139.0M$201.0M$123.0M
Total Liabilities$11.0M$14.0M$21.0M$60.0M$65.0M
Cash$160.0M$23.0M$33.0M$35.0M$21.0M
Borrowings$1.0M$3.0M$7.0M$47.0M$47.0M

Latest News

Trump cites national security to stop offshore wind development. Here's what to know Associated Press · Jul 16, 2026 Ingram Micro (INGM) Benefits From Resilient Enterprise Computing Demand Insider Monkey · Jul 16, 2026 Applied Digital (APLD) Expands North Dakota AI Campus on Schedule Insider Monkey · Jul 16, 2026 Bassett Announces Regular Quarterly Dividend GlobeNewswire · Jul 16, 2026 Tesla's Robotaxi Just Launched in Miami. Here's How Small the Service Area Really Is Motley Fool · Jul 16, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-36.0M$-48.0M$-58.0M$-71.0M$-92.0M
Investing Cash Flow$-118.0M$42.0M$-6.0M$-107.0M$134.0M
Financing Cash Flow$0$1.0M$13.0M$0$1.0M
Net Cash Flow$-3.0M$-5.0M$10.0M$2.0M$-14.0M
Free Cash Flow$-37.0M$-49.0M$-58.0M$-71.0M$-92.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.12
EV / EBITDA-2.73
FCF Yield-35.61%
Quick Ratio3.56
Interest Coverage18.72
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CATBCatabasis Pharmaceuticals, Inc. $8.54 -6.97% -5.02 $234.86M 0.00%
CRGXCARGO Therapeutics, Inc. Common Stock $4.47 +0.00% -1.59 $216.19M 0.00%
LSBCFLakeShore Biopharma Co., Ltd $0.07 +0.00% -0.48 $2.76M 0.00%
SCPHscPharmaceuticals Inc. $5.67 +0.00% -7.99 $302.20M 0.00%
SLRNAcelyrin, Inc. $2.27 +0.00% -0.91 $229.17M 0.00%

About Inozyme Pharma, Inc.

Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.

Inozyme Pharma, Inc. is headquartered in US.

Inozyme Pharma, Inc. (INZY) stock trades at $4.00 with a market capitalization of $258.25M. The stock is valued at a price-to-earnings (P/E) ratio of -2.47, price-to-book of 4.34, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.72 and $6.24, and currently trades 35.9% below its 52-week high.

On profitability, Inozyme Pharma, Inc. generates a return on equity (ROE) of -102.90%, return on capital employed of -116.52%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.inozyme.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides